Supplementary Documents [IFRS]

Financial results for the first six months of the fiscal year 2025 (FY2025)

Astellas Pharma Inc.

- Q2 YTD/FY2025 Financial Results
  - ➢ Six months ended September 30, 2025
  - ➢ Three months ended September 30, 2025
- Pipeline list

[Six months ended September 30, 2025]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
Revenue	935.6	1,030.1	94.5	10.1%	1,912.3	1,930.0	2,030.0	6.2%
Cost of sales	173.8	200.4	26.5	15.3%	349.2	373.0	387.0	10.8%
Gross profit	761.8	829.8	68.0	8.9%	1,563.1	1,557.0	1,643.0	5.1%
SG&A expenses	406.4	403.8	-2.6	-0.6%	843.0	805.0	831.0	-1.4%
XTANDI co-promotion fee in the United States	126.0	127.2	1.1	0.9%	252.6	229.0	245.0	-3.0%
SG&A excl. the above	280.4	276.7	-3.7	-1.3%	590.5	576.0	586.0	-0.8%
Ratio to Revenue	30.0%	26.9%			30.9%	29.8%	28.9%	
R&D expenses	172.3	143.3	-29.0	-16.9%	327.7	342.0	322.0	-1.7%
Ratio to Revenue	18.4%	13.9%			17.1%	17.7%	15.9%	
Amortisation of intangible assets	69.2	65.5	-3.7	-5.4%	136.8			
Gain on divestiture of intangible assets	0.9	4.0	3.1	341.1%	1.0			
Share of profit (loss) of investments accounted for using equity method	1.4	-1.6	-3.0	-	-0.3			
Other income	4.5	5.2	0.7	16.0%	20.3			
Net foreign exchange gains	-	0.5	0.5	-	-			
Fair value remeasurements on contingent consideration	2.6	4.1	1.4	53.6%	16.7			
Other expenses	26.9	25.4	-1.6	-5.8%	235.8			
Impairment losses for intangible assets	0.7	16.4	15.7	-	187.6			
Restructuring costs	7.9	4.9	-2.9	-37.5%	15.5			
Net foreign exchange losses	12.2	-	-12.2	-	18.6			
Fair value remeasurements on contingent consideration	0.7	1.2	0.5	79.1%	-			
Operating profit	93.7	199.4	105.7	112.8%	41.0	160.0	240.0	484.8%
Ratio to Revenue	10.0%	19.4%			2.1%	8.3%	11.8%	
Finance income	4.9	3.8	-1.1	-21.7%	7.9			
Finance expenses	9.5	8.6	-1.0	-10.0%	17.7			
Profit before tax	89.0	194.6	105.6	118.6%	31.2	150.0	230.0	636.3%
Income tax expense	15.5	47.0	31.4	202.4%	-19.5			
Profit	73.5	147.6	74.1	100.8%	50.7	130.0	180.0	254.7%
Comprehensive income	1.4	164.6	163.2	-	48.9			

2. Consolidated Results (Core Basis)

Unit: B¥

	FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
Revenue	935.6	1,030.1	94.5	10.1%	1,912.3	1,930.0	2,030.0	6.2%
Cost of sales	173.8	200.4	26.5	15.3%	349.2	373.0	387.0	10.8%
Gross profit	761.8	829.8	68.0	8.9%	1,563.1	1,557.0	1,643.0	5.1%
SG&A expenses	406.4	403.8	-2.6	-0.6%	843.0	805.0	831.0	-1.4%
XTANDI co-promotion fee in the United States	126.0	127.2	1.1	0.9%	252.6	229.0	245.0	-3.0%
SG&A excl. the above	280.4	276.7	-3.7	-1.3%	590.5	576.0	586.0	-0.8%
Ratio to Revenue	30.0%	26.9%			30.9%	29.8%	28.9%	
R&D expenses	172.3	143.3	-29.0	-16.9%	327.7	342.0	322.0	-1.7%
Ratio to Revenue	18.4%	13.9%			17.1%	17.7%	15.9%	
Operating profit	183.1	282.6	99.6	54.4%	392.4	410.0	490.0	24.9%
Ratio to Revenue	19.6%	27.4%			20.5%	21.2%	24.1%	
Finance income	4.9	3.8	-1.1	-21.7%	7.9			
Finance expenses	9.5	8.6	-1.0	-10.0%	17.7			
Profit before tax	178.4	277.9	99.5	55.8%	382.6			
Income tax expense	37.6	66.4	28.8	76.5%	87.0			
Profit	140.8	211.5	70.7	50.2%	295.7	304.0	365.0	23.4%

3. Exchange Rate

Unit: yen

	FY24 APR. - SEP.Ave.	FY25 APR. - SEP.Ave.	FY24 End	FY25 Q2 End	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year
USD/Yen	152	146	150	148	152	140	145
EUR/Yen	166	168	162	174	164	160	170

* Fx impacts: Revenue -22.2 billion yen and Core operating profit -4.5 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY24 APR. - SEP.			FY25 APR. - SEP.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	**935.6**	**-**	**935.6**	**1,030.1**	**-**	**1,030.1**
Cost of sales	173.8	-	173.8	200.4	-	200.4
Gross profit	**761.8**	**-**	**761.8**	**829.8**	**-**	**829.8**
SG&A expenses	406.4	-	406.4	403.8	-	403.8
R&D expenses	172.3	-	172.3	143.3	-	143.3
Amortisation of intangible assets *	69.2	-69.2	-	65.5	-65.5	-
Gain on divestiture of intangible assets *	0.9	-0.9	-	4.0	-4.0	-
Share of profit (loss) of investments accounted for using equity method *	1.4	-1.4	-	-1.6	1.6	-
Other income *	4.5	-4.5	-	5.2	-5.2	-
Other expenses *	26.9	-26.9	-	25.4	-25.4	-
Operating profit	**93.7**	**89.3**	**183.1**	**199.4**	**83.3**	**282.6**
Finance income	4.9	-	4.9	3.8	-	3.8
Finance expenses	9.5	-	9.5	8.6	-	8.6
Profit before tax	**89.0**	**89.3**	**178.4**	**194.6**	**83.3**	**277.9**
Income tax expense	15.5	22.1	37.6	47.0	19.4	66.4
Profit	**73.5**	**67.2**	**140.8**	**147.6**	**63.8**	**211.5**

* 'Amortisation of intangible assets', 'Gain on divestiture of intangible assets', 'Share of profit (loss) of investments accounted for using equity method', 'Other income' and 'Other expenses' are excluded from Core basis results.
"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

Unit: B¥

		FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
Revenue		935.6	1,030.1	94.5	10.1%	1,912.3	1,930.0	2,030.0	6.2%
	Japan	133.5	142.9	9.4	7.0%	267.0	285.0	281.0	5.2%
	Ratio to Revenue	14.3%	13.9%			14.0%	14.8%	13.8%	
	United States	419.3	457.1	37.9	9.0%	866.4	856.0	901.0	4.0%
	Ratio to Revenue	44.8%	44.4%			45.3%	44.4%	44.4%	
	Established Markets	240.0	264.9	24.9	10.4%	485.4	492.0	529.0	9.0%
	Ratio to Revenue	25.7%	25.7%			25.4%	25.5%	26.1%	
	China	37.7	49.7	12.1	32.0%	78.3	89.0	94.0	20.1%
	Ratio to Revenue	4.0%	4.8%			4.1%	4.6%	4.6%	
	International Markets	100.0	111.5	11.5	11.5%	203.5	202.0	219.0	7.6%
	Ratio to Revenue	10.7%	10.8%			10.6%	10.5%	10.8%	

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

6. Per Share Information

	FY24 APR. - SEP.	FY25 APR. - SEP.	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year
The number of shares issued (thousand)	1,809,663	1,809,663	1,809,663		
Treasury Shares (thousand)	19,555	18,447	19,353		
The number of shares issued after deducting Treasury Shares (thousand)	1,790,107	1,791,215	1,790,309		
Earnings per share (yen)	41.06	82.44	28.35	72.61	100.50
Earnings per share (yen) core basis	78.62	118.08	165.17	169.80	203.79
Dividend per share (yen)	37	39	74	78	78

- The numbers of shares stated in the business report are presented by disregarding any number of shares less than the specified units.

7. Investment in Property, Plant and Equipment
Depreciation/Amortisation

Unit: B¥

	FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
Investment in Property, Plant and Equipment	28.7	16.9	-11.7	-40.9%	47.8	55.0	55.0	15.1%
Depreciation (PP&E)	22.3	21.8	-0.5	-2.1%	44.9	45.0	45.0	0.2%
Amortisation of Intangible Assets (incl. software, etc.)	78.0	73.3	-4.7	-6.0%	154.2	155.0	155.0	0.5%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

8. Sales of major products

1) Global

Unit: B¥

		FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
PADCEV		75.4	102.5	27.1	35.9%	164.1	200.0	210.0	28.0%
	Japan	4.9	10.1	5.2	105.0%	12.6	27.0	22.0	74.6%
	United States	53.1	60.4	7.2	13.6%	109.1	111.0	120.0	10.0%
	Established Markets	15.0	20.1	5.1	34.1%	32.7	40.0	46.0	40.7%
	China	0.2	7.2	7.0	-	3.9	12.0	12.0	207.7%
	International Markets	2.1	4.6	2.5	115.5%	5.7	9.0	9.0	57.9%
IZERVAY		28.1	34.1	6.0	21.4%	58.3	105.0	80.0	37.2%
	United States	28.1	34.1	6.0	21.4%	58.3	105.0	80.0	37.2%
VEOZAH		14.8	22.9	8.1	54.7%	33.8	50.0	50.0	47.9%
	United States	13.6	20.4	6.8	50.4%	30.8	39.0	42.0	36.4%
	Established Markets	1.1	2.1	0.9	83.9%	2.7	8.0	6.0	122.2%
	International Markets	0.1	0.4	0.3	478.5%	0.3	1.0	1.0	233.3%
VYLOY		1.2	26.6	25.3	-	12.2	40.0	60.0	391.8%
	Japan	1.2	6.4	5.2	421.4%	5.2	14.0	15.0	188.5%
	United States	-	12.2	12.2	-	4.9	16.0	28.0	471.4%
	Established Markets	-	4.3	4.3	-	2.2	5.0	8.0	263.6%
	China	-	3.2	3.2	-	-	4.0	6.0	-
	International Markets	-	0.5	0.5	-	-	1.0	1.0	-
XOSPATA		34.8	34.4	-0.4	-1.1%	68.0	75.0	70.0	2.9%
	Japan	2.4	2.5	0.1	5.4%	4.7	6.0	5.0	6.4%
	United States	17.8	15.3	-2.5	-14.1%	35.0	36.0	33.0	-5.7%
	Established Markets	9.1	11.4	2.3	25.2%	18.9	19.0	21.0	11.1%
	China	3.0	2.0	-1.0	-34.6%	3.9	5.0	5.0	28.2%
	International Markets	2.5	3.2	0.7	30.0%	5.5	7.0	7.0	27.3%
XTANDI		451.7	477.0	25.3	5.6%	912.3	868.0	938.0	2.8%
	Japan	28.8	32.1	3.4	11.7%	57.9	60.0	64.0	10.5%
	United States	245.2	247.8	2.6	1.1%	491.7	446.0	477.0	-3.0%
	Established Markets	131.7	141.3	9.6	7.3%	262.1	261.0	281.0	7.2%
	China	6.9	10.7	3.8	55.6%	16.3	18.0	22.0	35.0%
	International Markets	39.2	45.0	5.9	15.0%	84.3	82.0	94.0	11.5%
BETANIS/MYRBETRIQ/BETMIGA		77.5	86.5	8.9	11.5%	170.0	134.0	163.0	-4.1%
PROGRAF		103.9	103.2	-0.7	-0.7%	201.0	186.0	196.0	-2.5%

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.
- PADCEV (United States): Co-promotion revenue from Pfizer
- VEOZAH: Approved as “VEOZA” in ex-US

2) Revenue by region

(1) Japan

Unit: B¥

	FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
Revenue	133.5	142.9	9.4	7.0%	267.0	285.0	281.0	5.2%
PADCEV	4.9	10.1	5.2	105.0%	12.6	27.0	22.0	74.6%
VYLOY	1.2	6.4	5.2	421.4%	5.2	14.0	15.0	188.5%
XOSPATA	2.4	2.5	0.1	5.4%	4.7	6.0	5.0	6.4%
XTANDI	28.8	32.1	3.4	11.7%	57.9	60.0	64.0	10.5%
BETANIS	12.5	11.1	-1.4	-10.9%	24.6	24.0	23.0	-6.5%
PROGRAF (Including GRACEPTOR)	12.0	9.3	-2.8	-23.0%	21.2	18.0	18.0	-15.1%
SUGLAT [Family]	13.5	12.2	-1.3	-9.8%	26.4	24.0	24.0	-9.1%
BLINCYTO	6.5	7.3	0.8	12.5%	13.4			
EVENITY	27.4	34.3	6.9	25.1%	57.9			

(2) United States

Unit: M$

	FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
Revenue	2,750	3,131	380	13.8%	5,683	6,120	6,210	9.3%
PADCEV	349	413	65	18.6%	716	790	830	15.9%
IZERVAY	184	234	49	26.8%	382	750	550	44.0%
VEOZAH	89	140	51	57.0%	202	280	290	43.6%
VYLOY	-	84	84	-	32	120	190	493.8%
XOSPATA	117	105	-12	-10.4%	230	260	230	0.0%
XTANDI	1,608	1,697	89	5.5%	3,225	3,180	3,290	2.0%
MYRBETRIQ	160	211	51	32.1%	410	210	380	-7.3%
CRESEMBA	147	172	25	16.9%	310	350	350	12.9%

(3) Established Markets

Unit: M€

	FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
Revenue	1,448	1,575	127	8.8%	2,967	3,070	3,110	4.8%
PADCEV	90	120	29	32.2%	200	250	270	35.0%
VEOZA	7	12	6	81.3%	17	50	40	135.3%
VYLOY	-	26	26	-	13	30	50	284.6%
XOSPATA	55	68	13	23.4%	115	120	120	4.3%
XTANDI	795	840	46	5.8%	1,602	1,630	1,650	3.0%
BETMIGA	183	203	21	11.4%	382	390	390	2.1%
PROGRAF	226	227	1	0.4%	459	440	450	-2.0%

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

	FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
Revenue	37.7	49.7	12.1	32.0%	78.3	89.0	94.0	20.1%
PADCEV	0.2	7.2	7.0	-	3.9	12.0	12.0	207.7%
VYLOY	-	3.2	3.2	-	-	4.0	6.0	-
XOSPATA	3.0	2.0	-1.0	-34.6%	3.9	5.0	5.0	28.2%
XTANDI	6.9	10.7	3.8	55.6%	16.3	18.0	22.0	35.0%
PROGRAF	21.9	21.5	-0.3	-1.5%	43.0	40.0	40.0	-7.0%

- China: China, Hong Kong

(5) International Markets

Unit: B¥

	FY24 APR. - SEP.	FY25 APR. - SEP.	Change	Change (%)	FY24 Full Year	Initial Forecasts FY25 Full Year	Revised Forecasts FY25 Full Year	Change from FY24 Change (%)
Revenue	100.0	111.5	11.5	11.5%	203.5	202.0	219.0	7.6%
PADCEV	2.1	4.6	2.5	115.5%	5.7	9.0	9.0	57.9%
VEOZA	0.1	0.4	0.3	478.5%	0.3	1.0	1.0	233.3%
VYLOY	-	0.5	0.5	-	-	1.0	1.0	-
XOSPATA	2.5	3.2	0.7	30.0%	5.5	7.0	7.0	27.3%
XTANDI	39.2	45.0	5.9	15.0%	84.3	82.0	94.0	11.5%
BETMIGA	9.6	9.9	0.3	3.3%	18.8	17.0	19.0	1.1%
PROGRAF	27.3	29.0	1.7	6.2%	51.4	48.0	52.0	1.2%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

9. Consolidated statements of financial position

Unit: B¥

	FY24 End	FY25 Q2 End	Change
Assets	**3,339.5**	**3,450.3**	**110.7**
Non-current assets	**2,138.2**	**2,081.5**	**-56.7**
Property, plant and equipment	328.9	334.2	5.3
Goodwill	415.2	412.7	-2.5
Intangible assets	1,123.7	1,041.4	-82.3
Trade and other receivables	18.5	18.4	-0.0
Investments accounted for using equity method	19.0	17.9	-1.1
Deferred tax assets	98.1	114.8	16.7
Other financial assets	106.2	112.3	6.1
Other non-current assets	28.6	29.6	1.0
Current assets	**1,201.3**	**1,368.8**	**167.5**
Inventories	297.3	310.0	12.8
Trade and other receivables	632.5	702.9	70.4
Income tax receivable	13.7	13.4	-0.3
Other financial assets	29.9	8.7	-21.3
Other current assets	39.2	46.3	7.1
Cash and cash equivalents	188.4	287.1	98.7
Assets held for sale	0.4	0.4	0.0

Unit: B¥

	FY24 End	FY25 Q2 End	Change
Equity and Liabilities	**3,339.5**	**3,450.3**	**110.7**
Equity	**1,513.3**	**1,612.4**	**99.2**
Equity attributable to owners of the parent	**1,513.3**	**1,612.4**	**99.2**
Share capital	103.0	103.0	-
Capital surplus	185.3	184.1	-1.2
Treasury shares	-37.5	-35.5	2.0
Retained earnings	740.9	822.9	82.0
Other components of equity	521.6	537.9	16.4
Liabilities	**1,826.3**	**1,837.9**	**11.6**
Non-current liabilities	**764.7**	**512.4**	**-252.3**
Bonds and borrowings	564.9	320.0	-244.9
Income tax payable	3.2	7.7	4.5
Deferred tax liabilities	5.4	5.6	0.2
Retirement benefit liabilities	22.7	22.3	-0.4
Provisions	8.1	5.2	-2.9
Other financial liabilities	106.8	101.1	-5.7
Other non-current liabilities	53.6	50.5	-3.1
Current liabilities	**1,061.6**	**1,325.5**	**263.8**
Bonds and borrowings	266.5	420.5	154.0
Trade and other payables	187.8	168.7	-19.2
Income tax payable	34.5	46.1	11.6
Provisions	17.3	20.9	3.7
Other financial liabilities	20.1	24.1	3.9
Other current liabilities	535.3	645.2	109.9

10. Employees

Number of employees

	FY24 Q2 End	FY25 Q2 End
Total	13,514	13,672

	FY24 Q4 End
Total	13,643

11. Shareholders

	FY24 Q2 End	FY25 Q2 End
Banks	36.5%	35.2%
Securities	6.5%	7.1%
Other companies	3.3%	2.3%
Foreign companies	40.0%	38.9%
Individuals and others	13.6%	16.5%
Treasury Stock*	0.0%	0.0%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

[Three months ended September 30, 2025]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY25			
	APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
Revenue	505.8	6.9%	524.3	13.4%
Cost of sales	94.8	4.1%	105.5	27.6%
Gross profit	411.0	7.6%	418.8	10.3%
SG&A expenses	197.0	-4.8%	206.8	3.7%
XTANDI co-promotion fee in the United States	62.9	2.1%	64.3	-0.3%
SG&A excl. the above	134.1	-7.7%	142.6	5.5%
Ratio to Revenue	26.5%		27.2%	
R&D expenses	71.7	-17.4%	71.6	-16.3%
Ratio to Revenue	14.2%		13.7%	
Amortisation of intangible assets	32.8	-6.4%	32.7	-4.4%
Gain on divestiture of intangible assets	3.7	306.9%	0.3	-
Share of profit (loss) of investments accounted for using equity method	-1.6	-	0.0	-
Other income	4.4	-10.8%	0.8	-
Net foreign exchange gains	-	-	0.5	-
Fair value remeasurements on contingent consideration	4.0	97.7%	0.0	-93.2%
Other expenses	21.3	105.5%	4.0	-75.6%
Impairment losses for intangible assets	13.6	-	2.8	-
Restructuring costs	2.8	8.7%	2.1	-59.9%
Net foreign exchange losses	2.3	-	-2.3	-
Fair value remeasurements on contingent consideration	0.7	-87.0%	0.4	-
Operating profit	94.6	86.8%	104.7	143.3%
Ratio to Revenue	18.7%		20.0%	
Finance income	1.7	-61.5%	2.2	297.5%
Finance expenses	5.9	31.2%	2.7	-46.6%
Profit before tax	90.4	79.1%	104.2	170.3%
Income tax expense	22.0	70.6%	25.0	846.6%
Profit	68.4	82.0%	79.2	120.6%
Comprehensive income	34.9	-76.7%	129.7	-

2. Consolidated Results (Core Basis)

Unit: B¥

	FY25			
	APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
Revenue	505.8	6.9%	524.3	13.4%
Cost of sales	94.8	4.1%	105.5	27.6%
Gross profit	411.0	7.6%	418.8	10.3%
SG&A expenses	197.0	-4.8%	206.8	3.7%
XTANDI co-promotion fee in the United States	62.9	2.1%	64.3	-0.3%
SG&A excl. the above	134.1	-7.7%	142.6	5.5%
Ratio to Revenue	26.5%		27.2%	
R&D expenses	71.7	-17.4%	71.6	-16.3%
Ratio to Revenue	14.2%		13.7%	
Operating profit	142.3	61.1%	140.4	48.1%
Ratio to Revenue	28.1%		26.8%	
Finance income	1.7	-61.5%	2.2	297.5%
Finance expenses	5.9	31.2%	2.7	-46.6%
Profit before tax	138.0	56.6%	139.8	54.9%
Income tax expense	33.3	58.8%	33.1	98.7%
Profit	104.7	56.0%	106.7	45.0%

3. Revenue by Region

Unit: B¥

		FY25			
		APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
Revenue		505.8	6.9%	524.3	13.4%
	Japan	68.9	3.4%	74.0	10.7%
	Ratio to Revenue	13.6%		14.1%	
	United States	224.7	6.0%	232.4	12.2%
	Ratio to Revenue	44.4%		44.3%	
	Established Markets	128.8	6.4%	136.1	14.4%
	Ratio to Revenue	25.5%		26.0%	
	China	29.4	57.8%	20.3	6.8%
	Ratio to Revenue	5.8%		3.9%	
	International Markets	53.2	2.3%	58.3	21.5%
	Ratio to Revenue	10.5%		11.1%	

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

4. Investment in Property,Plant and Equipment
Depreciation/Amortisation

Unit: B¥

	FY25			
	APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
Investment in Property, Plant and Equipment	4.8	-64.1%	12.1	-20.2%
Depreciation (PP&E)	11.1	2.2%	10.7	-6.3%
Amortisation of Intangible Assets (incl. software, etc.)	36.7	-6.9%	36.6	-5.2%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

		FY25			
		APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
PADCEV		55.5	44.6%	46.9	26.9%
	Japan	5.1	102.3%	5.0	107.8%
	United States	31.7	16.7%	28.7	10.4%
	Established Markets	9.5	26.1%	10.6	42.3%
	China	7.4	-	-0.2	-
	International Markets	1.8	62.6%	2.8	171.8%
IZERVAY		15.9	25.2%	18.2	18.3%
	United States	15.9	25.2%	18.2	18.3%
VEOZAH		9.6	45.6%	13.3	62.0%
	United States	8.6	39.7%	11.9	59.2%
	Established Markets	0.9	107.2%	1.2	69.4%
	International Markets	0.1	861.7%	0.2	366.6%
VYLOY		14.0	-	12.5	-
	Japan	3.1	791.2%	3.3	274.4%
	United States	5.9	-	6.3	-
	Established Markets	1.7	-	2.7	-
	China	3.3	-	-0.1	-
	International Markets	0.1	-	0.3	-
XOSPATA		17.0	-1.9%	17.5	-0.3%
	Japan	1.3	3.8%	1.2	7.2%
	United States	7.4	-17.8%	7.9	-10.5%
	Established Markets	5.6	20.8%	5.8	29.7%
	China	1.0	-26.6%	1.0	-41.3%
	International Markets	1.7	57.0%	1.5	9.0%
XTANDI		233.0	3.9%	244.0	7.3%
	Japan	15.9	7.1%	16.2	16.6%
	United States	122.6	2.4%	125.2	-0.1%
	Established Markets	69.5	5.7%	71.8	8.8%
	China	4.8	58.3%	5.9	53.4%
	International Markets	20.2	-3.2%	24.8	35.9%
BETANIS/MYRBETRIQ/BETMIGA		43.0	-6.8%	43.5	38.4%
PROGRAF		51.2	-4.9%	52.0	3.9%

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.
- PADCEV (United States): Co-promotion revenue from Pfizer
- VEOZAH: Approved as “VEOZA” in ex-US

2）Revenue by region

(1) Japan

Unit: B¥

	FY25			
	APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
Revenue	68.9	3.4%	74.0	10.7%
PADCEV	5.1	102.3%	5.0	107.8%
VYLOY	3.1	791.2%	3.3	274.4%
XOSPATA	1.3	3.8%	1.2	7.2%
XTANDI	15.9	7.1%	16.2	16.6%
BETANIS	5.7	-14.3%	5.5	-7.1%
PROGRAF (Including GRACEPTOR)	4.6	-27.4%	4.6	-18.2%
SUGLAT [Family]	6.3	-10.2%	5.9	-9.3%
BLINCYTO	3.5	8.2%	3.9	16.7%
EVENITY	16.5	20.1%	17.8	30.1%

(2) United States

Unit: M$

	FY25			
	APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
Revenue	1,555	14.3%	1,576	13.4%
PADCEV	219	25.9%	194	11.4%
IZERVAY	110	35.0%	124	20.2%
VEOZAH	59	50.7%	81	62.0%
VYLOY	41	-	43	-
XOSPATA	51	-11.3%	54	-9.5%
XTANDI	848	10.4%	849	1.1%
MYRBETRIQ	107	-11.1%	104	163.4%
CRESEMBA	80	14.5%	92	19.1%

(3) Established Markets

Unit: M€

	FY25			
	APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
Revenue	786	8.9%	790	8.7%
PADCEV	58	29.1%	62	35.4%
VEOZA	5	112.1%	7	62.5%
VYLOY	10	-	16	-
XOSPATA	34	23.7%	34	23.2%
XTANDI	424	8.3%	417	3.3%
BETMIGA	102	10.4%	102	12.3%
PROGRAF	113	-1.1%	114	2.0%

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

	FY25			
	APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
Revenue	29.4	57.8%	20.3	6.8%
PADCEV	7.4	-	-0.2	-
VYLOY	3.3	-	-0.1	-
XOSPATA	1.0	-26.6%	1.0	-41.3%
XTANDI	4.8	58.3%	5.9	53.4%
PROGRAF	10.4	-7.5%	11.2	4.7%

- China: China, Hong Kong

(5) International Markets

Unit: B¥

	FY25			
	APR. - JUN. (Quarterly)	Change (%)	JUL. - SEP. (Quarterly)	Change (%)
Revenue	53.2	2.3%	58.3	21.5%
PADCEV	1.8	62.6%	2.8	171.8%
VEOZA	0.1	861.7%	0.2	366.6%
VYLOY	0.1	-	0.3	-
XOSPATA	1.7	57.0%	1.5	9.0%
XTANDI	20.2	-3.2%	24.8	35.9%
BETMIGA	5.0	1.3%	4.9	5.3%
PROGRAF	14.9	3.7%	14.1	9.0%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China. As of Oct 2025

Underlined items indicate changes from the previous announcement in Jul 2025.

Strategic Brands (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Cisplatin-ineligible muscle-invasive bladder cancer (combo with pembrolizumab)	<u>US</u> <u>Filed (Oct 2025)</u>	In-house [Co-development with Pfizer]	
			Cisplatin-eligible muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-II		
			Acute myeloid leukemia in pediatric patients	P-III		
			<u>ALK-positive non-small cell lung cancer</u>	<u>P-I</u>		
zolbetuximab IMAB362 (VYLOY)	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma (combo with pembrolizumab and chemotherapy)	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		

Strategic Brands (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
fezolinetant **ESN364** **(VEOZAH***)**	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China P-III Japan P-III	In-house (Ogeda)	
			Vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy	P-III		
avacincaptad pegol **(IZERVAY)**	Pegylated RNA aptamer	Complement C5 inhibitor	Geographic atrophy secondary to age-related macular degeneration	Japan Approved (Sep 2025)	In-house (Iveric Bio)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.
*** Approved as "VEOZA" in ex-US.

Updates from the previous announcement (Jul 2025):
enfortumab vedotin: Filed in US in Oct 2025 for cisplatin-ineligible muscle-invasive bladder cancer.
gilteritinib: Entered into Phase 1 for ALK-positive non-small cell lung cancer.
avacincaptad pegol: Approved in Japan in Sep 2025 for suppression of geographic atrophy growth in atrophic age-related macular degeneration. Discontinued Phase 2 program for Stargardt disease.

Programs with Focus Area approach

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Immuno-oncology	**ASP1570**	Small molecule	DGKζ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
	ASP1002	Antibody	Anti-Claudin 4 and anti-CD137 bispecific antibody	Cancer	P-I	In-house	
Targeted Protein Degradation	**ASP3082**	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
	ASP4396	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
	ASP5834	Small molecule	Pan-KRAS degrader	Cancer	P-I	In-house	
Genetic regulation	**resamirigene bilparvovec AT132**	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	zocaglusagene nuzaparvovec AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-II	In-house (Audentes Therapeutics)	
Blindness and Regeneration	**ASP7317**	Cell therapy	Retinal pigment epithelial cells	Geographic atrophy secondary to age-related macular degeneration	P-I	In-house (Ocata Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Jul 2025):
ASP5834: Entered into Phase 1 for cancer.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron **YM178**	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients (aged 6 months to less than 3 years)	Europe P-III	In-house	
roxadustat **ASP1517/FG-4592**	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
abiraterone decanoate **ASP5541/PRL-02**	Small molecule	CYP17 lyase inhibitor	Prostate cancer	P-II	In-house (Propella Therapeutics)	
ASP546C/XNW27011	Antibody-drug conjugate (ADC)	Claudin 18.2-targeted ADC	Cancer	P-I	Evopoint Biosciences	Astellas has worldwide rights excluding China's mainland, Hong Kong, Macau, and
ASP5502	Small molecule	STING inhibitor	Primary Sjogren’s syndrome	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Jul 2025):
abiraterone decanoate/ASP5541: Entered into Phase 2 for prostate cancer.

Rx+ Program

As of Oct 2025

Underlined items indicate changes from the previous announcement in Jul 2025.

Category	Program	Concept	Status*	Partner	Remarks
Digital health	**BlueStar**	Digital therapeutic for the management of diabetes	Pivotal study (Japan)	Welldoc Roche Diabetes Care Japan	
Drug-device combination	**pudexacianinium chloride ASP5354**	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	
Implantable medical device	**Akyva**	Implantable device for underactive bladder	FDA approved to enter into early feasibility study. Enrolling subjects in Australia	(iota Biosciences)	

* The list shows the most advanced stage if the stages are different depending on the region.

Updates from the previous announcement (Jul 2025):
Akyva: Enrolling subjects in Australia.